First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients

(University of Texas M. D. Anderson Cancer Center) In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news